[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567749":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":32,"locations":39,"responsibleParty":151,"collaborators":153,"id":156,"slug":31,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":31,"eligibilityCriteria":161,"healthyVolunteers":157,"sex":162,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":31,"studyType":168,"phases":169,"briefSummary":171,"conditions":172,"keywords":193,"overallStatus":42,"whyStopped":31,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":217},{"fullName":5,"class":6},"Intellia Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"nexiguran ziclumeran","EXPERIMENTAL","nexiguran ziclumeran 55 mg by single IV infusion",[13],"Biological: nexiguran ziclumeran",{"label":15,"type":16,"description":17,"interventionNames":18},"Normal Saline","PLACEBO_COMPARATOR","Placebo; Normal saline (0.9% NaCl) by single IV infusion",[19],"Drug: Normal Saline as Placebo",[21,26],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL",[9],[25],"NTLA-2001",{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Normal Saline as Placebo","Normal saline (0.9% NaCl) by single IV infusion",[15],null,[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Trial Manager at Intellia","CONTACT","1-857-285-6200","6","medicalinformation@intelliatx.com",[40,51,56,64,73,81,89,97,106,114,119,129,134,142],{"facility":41,"status":42,"city":43,"state":31,"zip":31,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":31},"Hospital Británico de Buenos Aires","RECRUITING","Buenos Aires","Argentina",{"type":46,"coordinates":47},"Point",[48,49],-58.37723,-34.61315,{"lat":49,"lon":48},{"facility":52,"status":42,"city":43,"state":31,"zip":31,"country":44,"cosmosGeoPoint":53,"geoPoint":55,"contacts":31},"Hospital Italiano de Buenos Aires (HIBA)",{"type":46,"coordinates":54},[48,49],{"lat":49,"lon":48},{"facility":57,"status":42,"city":58,"state":31,"zip":31,"country":44,"cosmosGeoPoint":59,"geoPoint":63,"contacts":31},"Hospital El Cruce","San Juan Bautista",{"type":46,"coordinates":60},[61,62],-58.27623,-34.80896,{"lat":62,"lon":61},{"facility":65,"status":42,"city":66,"state":31,"zip":31,"country":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":31},"Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)","Campinas","Brazil",{"type":46,"coordinates":69},[70,71],-47.06083,-22.90556,{"lat":71,"lon":70},{"facility":74,"status":42,"city":75,"state":31,"zip":31,"country":67,"cosmosGeoPoint":76,"geoPoint":80,"contacts":31},"HCFMRP - Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto","Ribeirão Preto",{"type":46,"coordinates":77},[78,79],-47.81028,-21.1775,{"lat":79,"lon":78},{"facility":82,"status":42,"city":83,"state":31,"zip":31,"country":67,"cosmosGeoPoint":84,"geoPoint":88,"contacts":31},"Instituto de Educacao, Pesquisa e Gestao em Saude","Rio de Janeiro",{"type":46,"coordinates":85},[86,87],-43.18223,-22.90642,{"lat":87,"lon":86},{"facility":90,"status":42,"city":91,"state":31,"zip":31,"country":67,"cosmosGeoPoint":92,"geoPoint":96,"contacts":31},"PSEG Centro de Pesquisa Clinica S.A.","São Paulo",{"type":46,"coordinates":93},[94,95],-46.63611,-23.5475,{"lat":95,"lon":94},{"facility":98,"status":42,"city":99,"state":31,"zip":31,"country":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":31},"National Institute of Medical Sciences and Nutrition - Salvador Zubiran (INCMNSZ)","Tlalpan","Mexico",{"type":46,"coordinates":102},[103,104],-99.16206,19.29513,{"lat":104,"lon":103},{"facility":107,"status":42,"city":108,"state":31,"zip":31,"country":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":31},"National University Hospital","Singapore",{"type":46,"coordinates":110},[111,112],103.85007,1.28967,{"lat":112,"lon":111},{"facility":115,"status":42,"city":108,"state":31,"zip":31,"country":108,"cosmosGeoPoint":116,"geoPoint":118,"contacts":31},"Singapore General Hospital",{"type":46,"coordinates":117},[111,112],{"lat":112,"lon":111},{"facility":120,"status":121,"city":122,"state":31,"zip":31,"country":123,"cosmosGeoPoint":124,"geoPoint":128,"contacts":31},"National Taiwan University Hospital","ACTIVE_NOT_RECRUITING","Taipei","Taiwan",{"type":46,"coordinates":125},[126,127],121.52639,25.05306,{"lat":127,"lon":126},{"facility":130,"status":121,"city":122,"state":31,"zip":31,"country":123,"cosmosGeoPoint":131,"geoPoint":133,"contacts":31},"Taipei Veterans General Hospital",{"type":46,"coordinates":132},[126,127],{"lat":127,"lon":126},{"facility":135,"status":121,"city":136,"state":31,"zip":31,"country":123,"cosmosGeoPoint":137,"geoPoint":141,"contacts":31},"Chang Gung Medical Foundation - Linkou Branch","Taoyuan",{"type":46,"coordinates":138},[139,140],121.29696,24.99368,{"lat":140,"lon":139},{"facility":143,"status":42,"city":144,"state":31,"zip":31,"country":145,"cosmosGeoPoint":146,"geoPoint":150,"contacts":31},"Siriraj Hospital","Bangkok","Thailand",{"type":46,"coordinates":147},[148,149],100.50144,13.75398,{"lat":149,"lon":148},{"type":152,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[154],{"name":155,"class":6},"Regeneron Pharmaceuticals","100567749",false,"NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease","ALL","18 Years","85 Years",{"count":166,"type":167},60,"ESTIMATED","INTERVENTIONAL",[170],"PHASE3","This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192],"Neuromuscular Disease","Neuromuscular Diseases (NMD)","Neurodegenerative Disease","Neurodegenerative Disease, Hereditary","Neurodegenerative Diseases","Neuromuscular Diseases","Nerve Disorders","Nervous System Disease","Nervous System Diseases","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloidosis","Polyneuropathies","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors","Metabolic Diseases",[194,185,195,25,196,197,198,199,200,201,202,203,204,205,9,206,207],"TTR","Polyneuropathy","ATTR","ATTR-PN","ATTRv-PN","Transthyretin","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nex-z","CRISPR","2026-04-13",{"date":210,"type":211},"2026-04-16","ACTUAL",{"date":213,"type":211},"2024-11-22",{"date":215,"type":167},"2028-08",{"name":5,"class":6},14]